Dear Sir,
A recent paper by Bratusch-Marrain et al. [1] claims that acetylsalicylic acid impairs tissue sensitivity to insulin in healthy subjects and in Type 2 (non-insulin-dependent) diabetic patients. Moreover, the augmenting effect of acetylsaiicylic acid on insulin levels has been interpreted as the result of reduced insulin clearance rate rather than increased secretion [1] .
The suspicion that salicylate could produce an inhibitory effect on insulin-stimulated glucose uptake arose in the last decade, when it was seen that the augmentation of glucose-induced insulin responses in normal subjects after salicylate treatment was not associated with increased glucose utilization rates [2] . Later, we demonstrated that, in the absence of B-cell function in Type I (insulin-dependent) diabetic patients, salicylate treatment tended to increase rather than decrease glucose values [3, 4] . The finding supports the concept of a peripheral action of the compound opposing the effect of insulin. The analysis of glucose turnover in normal man during an infusion of salicylate [5] shows the association of increased insulin levels (glucagon unchanged) with low rates of glucose clearance and uptake. Thus, an effect of the impairment of tissue sensitivity to insulin by saiicylate was already documented early in this decade.
With regard to the second point of the paper, it must be kept in mind that the possibility that salicylate compounds may also impair hepatic insulin extraction had been proposed by Ratzmann et al. [6] in 1982. However, Prince et al. [7] , as well as our group [8] , found no alteration in the C-peptide-insulin relationship after either glucose or arginine administration in both normal subjects and Type 2 diabetic patients.
The problem is to relate the metabolic effects of salicylate in man with the presumed inhibition of endogenous prostaglandin synthesis. Prostaglandins of the E series have been shown to stimulate glucose uptake in vitro [9] , and prostaglandin inhibitors to depress mitochondrial pyruvate dehydrogenase activity in adipocytes, an effect which is reversed by by exogenous prostaglandin E2 [10] . On the other hand, the infusion of exogenous prostaglandins (El or E2) may counteract the potentiating effect of salicylate on glucose-induced insulin secretion in both healthy subjects [11] and in Type 2 diabetic patients [12] . These data seem to indicate that a possible mechanism by which salicylate compounds exert their multiple metabolic effects in man may be related to inhibition of endogenous prostaglandin E1 or E2 synthesis.
